Rigel Pharmaceuticals Inc
$ 40.17
2.42%
07 Aug - close price
- Market Cap 743,229,000 USD
- Current Price $ 40.17
- High / Low $ 41.13 / 39.51
- Stock P/E 2.38
- Book Value 22.77
- EPS 16.89
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.15 %
- ROE 1.27 %
- 52 Week High 52.24
- 52 Week Low 24.95
About
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$55.60
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-03-03 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-03-04 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-07 |
| Reported EPS | 0.88 | 0.44 | 1.1198 | 1.46 | 3.28 | 0.63 | 0.8 | 0.7 | -0.06 | -0.5 | 0.0042 | -0.3 |
| Estimated EPS | 0.91 | 0.87 | 1.2015 | 0.94 | 1.41 | 0.09 | 0.5789 | 0.06 | -0.18 | -0.27 | -0.03 | -0.66 |
| Surprise | -0.03 | -0.43 | -0.0817 | 0.52 | 1.87 | 0.54 | 0.2211 | 0.64 | 0.12 | -0.23 | 0.0342 | 0.36 |
| Surprise Percentage | -3.2967% | -49.4253% | -6.7998% | 55.3191% | 132.6241% | 600% | 38.1931% | 1066.6667% | 66.6667% | -85.1852% | 114% | 54.5455% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RIGL
2026-08-06 08:41:24
H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
2026-08-06 08:41:24
Rigel Pharmaceuticals (RIGL) saw its stock rally after its Q2 earnings release, with a 4.6% increase following a strong three-month run. The company maintained profitability with $17.3m in net income and $78.7m in total revenue, though revenue and EPS declined significantly year-over-year. While the company's existing products showed growth, concerns persist regarding the sustainability of its earnings due to reliance on one-time milestone payments and non-cash items, as well as significant future capital commitments.
2026-08-05 03:11:56
Rigel Pharmaceuticals reported strong Q2 2026 results, with commercial revenue growing 14% year-over-year, driven by record TAVALISSE sales and REZLIDHIA growth. The company is accelerating the launch of VEPPANU, an FDA-approved breast cancer therapy, which it expects to be its largest future revenue driver, and is advancing its R289 development pipeline with top-line data expected by year-end. Rigel also raised its full-year 2026 total revenue guidance to $285 million-$295 million, excluding VEPPANU sales, and anticipates positive net income for the year.
2026-08-05 02:43:19
Rigel Pharmaceuticals, Inc. (RIGL) published a slide deck in conjunction with their Q2 2026 earnings call. The company reported an EPS of $0.88, beating estimates by $0.96, and revenue of $78.70M, which also beat estimates by $23.43M despite a 22.60% year-over-year decrease. This article provides access to the earnings call presentation and related transcript and insights.
2026-08-04 21:11:56
Rigel Pharmaceuticals (RIGL) reported Q2 earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share, and significantly down from $3.28 per share a year ago. Despite missing EPS estimates, the company's Q2 revenues of $78.7 million surpassed the consensus estimate by 14.58%. Rigel's stock has underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #4 (Sell) due to an unfavorable estimate revisions trend.
2026-08-04 19:11:56
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models, highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies an exceptional short setup with a significant risk-reward ratio and outlines specific trading strategies for different risk profiles. The analysis includes multi-timeframe signal analysis and resistance/support levels for informed trading decisions.
